8 papers in the library · 28 citations · publishing 2024-2026
JAMA Network Open September 29, 2026 Otto Simonsson, Melissa Bradley, Joshua Curtis Black et al.
This cross-sectional study describes health outcomes attributed to recent use of psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a nationally representative survey of US adults.
Psychedelics September 29, 2026 Karilynn M Rockhill, Nicole Schow, Dean Garibaldi et al.
Objective In 2024, the United States had the highest prevalence of psychedelic use recorded, but reliability of self-report data in surveys has not been rigorously assessed. Our objective was to quantify the reliability of self-report across 17 psychedelic and dissociative substances in an adult population sampled from the National Survey Investigating Hallucinogenic Trends (NSIHT). Methods In...
Research Square May 19, 2026 Sunjuri Sun, Claudia Hanson, Peter S. Hendricks et al. preprint
As the cultural, scientific, and legal landscape surrounding psychedelics continues to shift toward greater access and acceptability, it is likely that increasing numbers of women of reproductive age may be exposed to these substances. Despite this, the evidence on antenatal exposure has not been systematically reviewed. To synthesize the human literature on child and maternal outcomes...
Journal of Medical Internet Research April 27, 2026 Karilynn M Rockhill, Elizabeth A Bemis, Nicole Schow et al. 2 citations
Mainstays of pharmacoepidemiology are large, representative, behavioral surveys, which focus on many drugs with few detailed behaviors. Smaller, targeted studies measure drug-specific patterns but without explicit generalizability assumptions; the evidence generated is narrow. In this cross-sectional survey study, we outline an estimation framework based on data fusion and combine two surveys:...
Journal of Psychoactive Drugs March 16, 2026 Faith E Lyons, Karilynn M Rockhill, Evelyn J Fox et al.
Expanding regulation and increased use of psychedelic substances requires surveillance of behaviors and health outcomes in the United States. Widely comprehendible terminology is important for surveys. The objective of this study was to determine what psychedelic terminology is preferred among adults who used a psychedelic in the past 12 months. A cross-sectional survey measuring psychedelic...
Annals of emergency medicine June 30, 2025 Joshua C. Black, Karilynn M Rockhill, Evelyn J Fox et al. 4 citations
Oregon and Colorado have legalized possession of natural psychedelic drugs. We assessed if travel to use psychedelics in decriminalized states is occurring and compared the use patterns of travelers with nontravelers. The National Survey Investigating Hallucinogen Trends is a cross-sectional behavioral survey fielded from April to June 2024 to every US state. The survey asks whether individuals...
American Journal of Public Health May 1, 2025 Karilynn M Rockhill, Joshua C. Black, Janetta Iwanicki et al. 17 citations
Objectives. To characterize present-day polysubstance use patterns in the general adult population. Methods. From a 2022 nationally representative survey in the United States, we defined polysubstance use as last 12-month use of 2 or more drugs (n = 15 800). Latent class analyses included medical (as indicated) and nonmedical (not as directed) use of prescription opioids, stimulants,...
Nature Mental Health May 1, 2024 Joshua C. Black, Andrew A. Monte, Nabarun Dasgupta et al. 5 citations
The encouraging results of late-phase clinical trials investigating psychedelic-assisted psychotherapy suggests that US Food and Drug Administration approval and subsequent expansion of use is imminent in the USA. Without fit-for-purpose postmarket surveillance to proactively monitor utilization by patients and providers, there is a risk that the real-world benefits of psychedelic-assisted...